TrialDiabetes, obesity & metabolism2022

Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes.

Klara R Klein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.